In order to achieve this, the European Commission has consistently advocated a policy of "tiered pricing" for medicines, combined with market segmentation between rich and poor countries.
Lai to panāktu, Eiropas Komisija zālēm pastāvīgi piemēro "cenu diferencēšanas" politiku apvienojumā ar tirgus segmentāciju, nošķirot valstis ar zemu un augstu labklājības līmeni.